United States Contract Manufacturing Services Market Size and Share
United States Contract Manufacturing Services Market Analysis by Mordor Intelligence
The United States contract manufacturing services market size reached USD 248.11 billion in 2025 and is projected to climb to USD 356.72 billion by 2030, translating into a 7.53% CAGR. Reshoring incentives under the Inflation Reduction Act are steering budget allocations toward domestic plants, redirecting work that once migrated offshore and widening the addressable base for the United States contract manufacturing services market.[1]Richard Michael, “Reshoring After the Inflation Reduction Act,” inspectioneering.com Stricter FDA quality-by-design rules reward providers equipped with in-line analytics and real-time release testing, enabling premium price realization and faster tech-transfer cycles.[2]U.S. Food & Drug Administration, “Quality by Design for ANDAs,” fda.gov Specialized demand for biologics and high-potency APIs further accelerates outsourcing because negative-pressure suites and advanced containment impose capital barriers too steep for many brand owners. Parallel growth in functional ready-to-drink beverages and plant-based convenience foods favours agile co-packers that can manage small-batch runs and sensitive ingredients without disrupting legacy high-volume lines. Although skilled-labour shortages and raw-material swings compress margins, strong policy tailwinds and regulatory complexity keep the United States contract manufacturing services market on a durable upward trajectory.[3]PepsiCo, “PepsiCo to Acquire poppi,” pepsico.com
Key Report Takeaways
- By pharmaceutical services, Finished Dosage Formulation captured 42.66% of 2024 revenue, while High-Potency API manufacturing is forecast to compound at 10.01% CAGR through 2030.
- By food processing and manufacturing, Convenience Foods commanded 37.42% of 2024 turnover; Plant-based Convenience Foods are positioned for a 9.83% CAGR to 2030.
- By beverage category, Bottled Water held 40.27% share in 2024, whereas Functional RTD Beverages are projected to expand at a 10.53% CAGR over the same horizon.
- By personal care, Skin Care represented 28.62% of 2024 sales, and Clean Beauty applications are set to rise at a 9.60% CAGR through 2030.
United States Contract Manufacturing Services Market Trends and Insights
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Surge in reshoring initiatives post-Inflation Reduction Act | +1.20% | National, with concentration in Midwest and South | Medium term (2-4 years) |
| Tightening U.S. FDA quality-by-design guidelines driving professional outsourcing | +1.80% | National, with emphasis on Northeast and West Coast | Short term (≤ 2 years) |
| Acceleration of biologics and HPAPI pipelines requiring specialized capacity | +2.10% | Northeast, West Coast, with expansion to South | Long term (≥ 4 years) |
| Beverage brands' pivot to functional/RTD formats needing agile co-packers | +0.90% | National, with regional specialization clusters | Medium term (2-4 years) |
| Corporate sustainability targets boosting demand for recyclable contract packaging | +0.70% | National, with early adoption in West Coast | Medium term (2-4 years) |
| DARPA and BARDA funding for rapid domestic surge-capacity platforms | +0.60% | National, with defense contractor concentration | Short term (≤ 2 years) |
| Source: Mordor Intelligence | |||
Surge in Reshoring Initiatives Post-Inflation Reduction Act
Federal tax credits tied to domestic content are shifting capital budgets toward U.S. factories, allowing the United States contract manufacturing services market to recapture production once located overseas. Contractors that can document Buy American compliance now secure multiyear agreements, particularly in pharmaceuticals and renewable-energy components. The advanced manufacturing production credit elevates margins for qualifying operations, encouraging accelerated groundbreakings in the Midwest and South where land and utilities cost less. Major pharmaceutical announcements such as Eli Lilly’s multi-site buildout topping USD 50 billion since 2020 illustrate the policy’s reach. Similar momentum appears in materials processing; Covestro’s EUR 35 million (USD 38 million) investment in Ohio polycarbonate output underscores cross-sector capital flow. These projects enlarge the skilled labour pool yet lead times for facility commissioning keep near-term capacity tight, preserving pricing leverage for incumbent contractors. In response, some producers lock in long-term offtake to hedge against future slot scarcity, cementing demand visibility for the United States contract manufacturing services market.
Tightening FDA Quality-by-Design Guidelines Driving Professional Outsourcing
Updated FDA guidance requires continuous monitoring, process analytical technology, and data-rich validation, raising the floor for compliant production. Many mid-tier drug developers deem internal upgrades uneconomic, opting instead for contractors already running real-time release platforms. These providers shorten commercialization timelines by up to 18 months, delivering a speed premium that translates into earlier revenue recognition for brand owners. M&A activity remains brisk as leading CDMOs buy assets with mature QbD infrastructure; PCI Pharma Services’ purchase of Ajinomoto Althea’s aseptic fill-finish network is emblematic.[4]BioProcess International, “PCI Bolsters Fill/Finish Capacity,” bioprocessintl.com The consequence is heightened consolidation inside the United States contract manufacturing services market, with scale players harvesting operational synergies while widening the compliance gap versus smaller rivals. Over the forecast window, incremental guidance on software assurance and continuous manufacturing is expected to keep capital intensity high, locking in the outsourcing thesis.
Acceleration of Biologics and HPAPI Pipelines Requiring Specialized Capacity
Growth in antibody-drug conjugates and highly potent oncology assets drives demand for negative-pressure suites, rigid isolators, and advanced operator-safety protocols unavailable in typical legacy plants. Few facilities meet both occupational exposure band limits and FDA sterility expectations, giving the scarce pool of qualified providers pricing power. Syngene’s acquisition of Emergent BioSolutions’ U.S. biologics site and Kindeva’s combination with Meridian illustrate how supply-side players scramble to secure GMP-ready real estate. Meanwhile, the BIOSECURE Act’s constraints on Chinese-owned facilities amplify the premium on domestic capacity. This environment emboldens long-term take-or-pay contracts wherein sponsors underwrite new suites to guarantee future access, further solidifying volume certainty for the United States contract manufacturing services market.
Beverage Brands’ Pivot to Functional/RTD Formats Needing Agile Co-Packers
Consumers gravitate to drinks fortified with probiotics, adaptogens, and vitamins, pushing beverage innovators into pilot-scale launches that rarely fit high-volume internal lines. Contract packers with batch-size agility and specialized filling gear become essential for prototype validation and rapid market rollout. Ingredient sensitivity necessitates cold-fill or aseptic processes that add technical complexity and justify premium co-packing rates. PepsiCo’s acquisition of prebiotic soda brand poppi highlights how incumbents buy portfolios rather than re-tool legacy assets, sustaining demand for flexible manufacturing slots. Regional co-packers respond by installing dedicated lanes for functional RTD beverages, bolstered by analytical labs that verify nutrient stability. These capabilities differentiate suppliers, attracting multi-year agreements that enlarge the revenue base of the United States contract manufacturing services market.
Restraints Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Persistent skilled-labor shortages inflating turnkey service pricing | -1.40% | National, with acute impacts in Midwest manufacturing hubs | Medium term (2-4 years) |
| Volatility in raw-material input costs compressing contractor margins | -1.10% | National, with commodity-intensive sectors most affected | Short term (≤ 2 years) |
| Legacy facility footprints limiting flexibility for short-run SKUs | -0.80% | National, with older industrial regions most constrained | Long term (≥ 4 years) |
| Heightened CFIUS scrutiny on foreign ownership of U.S. plants | -0.50% | National, with strategic sector concentration | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
Persistent Skilled-Labor Shortages Inflating Turnkey Service Pricing
Roughly 2.1 million manufacturing roles remain unfilled nationwide, and competition from technology and healthcare verticals elevates wage expectations for experienced technicians. High-potency suites, aseptic fill-finish lines, and continuous food-processing equipment require specialized certifications that shrink the eligible talent pool. Contract manufacturers raise hourly rates to retain staff, then pass higher costs into service quotes, nudging average turnkey project pricing upward across the United States contract manufacturing services market. Apprenticeship programs mitigate attrition yet require 12-18 months before yielding productivity, leaving an interim gap that automation only partially offsets. Geographic wage differentials further skew project-award patterns toward the South and Midwest, where lower cost-of-living indexes moderate labour premiums. Nevertheless, scarcity persists in niche skills such as sterile compounding, delaying schedule adherence for some GMP renovations.
Volatility in Raw-Material Input Costs Compressing Contractor Margins
Prices for pharmaceutical excipients, specialty chemicals, and packaging substrates swung more than 15% during 2024, and fixed-price contracts restrict immediate pass-through. Smaller contractors lacking hedge programs absorb margin hits, potentially limiting reinvestment in compliance upgrades. Inventory buffers become costlier as holding periods lengthen, especially for temperature-controlled inputs requiring energy-intensive storage. Energy itself represents 8–12% of manufacturing overhead and registers wide regional spreads, complicating bid parity across plants. In response, many providers adopt cost-plus models or shorten contract terms, transferring volatility risk to brand owners yet potentially sacrificing deal visibility. While some clients accept dynamic pricing, others seek multi-sourced frameworks, fragmenting volumes within the United States contract manufacturing services market and introducing scheduling inefficiencies that temper overall growth.
Segment Analysis
By Pharmaceutical Services: Specialized Suites Lift High-Potency Growth
Finished Dosage Formulation accounted for 42.66% of 2024 revenue, underscoring its role as the throughput anchor for the United States contract manufacturing services market share in life-science applications. High-Potency API manufacturing is forecast to deliver a 10.01% CAGR through 2030, the steepest curve in the pharmaceutical bucket, fuelled by oncology pipelines and complex conjugates demanding containment grades OEB 4-5. The United States contract manufacturing services market size for HPAPI work is projected to accelerate as brand owners underwrite new isolator trains to secure scarce capacity. Secondary Packaging keeps momentum amid federal serialization mandates that extend traceability to the unit level, making data-rich labelling a value driver. Throughout the period, automation and single-use technologies compress changeover times, enabling smaller batch sizes that align with precision-medicine strategies.
Complementing high-containment assets, small-molecule API production remains relevant for generic and specialty drugs that still require cost arbitration and cGMP compliance. Injectable Dose Formulation shows above-average expansion because parenteral delivery offers better bioavailability for biologics and long-acting injectables. Contract manufacturers widen pre-filled-syringe and cartridge lines, blending robotics with vision-inspection systems to assure sterile integrity. Investment examples include Evonik’s automated vial-filling program and PCI Pharma’s Rockford expansion, both reinforcing the capability gap between top-tier CDMOs and regional players. This divergence is expected to entrench tiered pricing within the United States contract manufacturing services market.
Note: Segment shares of all individual segments available upon report purchase
By Food Processing and Manufacturing: Plant-Based Innovation Reshapes Demand
Convenience Foods occupied 37.42% of 2024 turnover, cementing its position as the largest in the food domain of the United States contract manufacturing services market. Plant-based Convenience Foods, already benefiting from a 9.83% CAGR outlook, ride consumer shifts toward alternative proteins and clean-label nutrition. Shear-cell texturization and high-moisture extrusion necessitate specialized equipment, incentivizing brands to outsource rather than invest in asset-specific lines. The United States contract manufacturing services market size for alternative protein runs is expected to widen as startup incubators contract for pilot-scale volumes ahead of nationwide distribution.
Bakery Products continue to rely on contract manufacturers for gluten-free and artisan varieties where segregation from wheat-based inputs is mandatory. Similarly, Dairy Products outsourcing grows on the back of lactose-free and plant-based variants that require separate pasteurization flows. R&D services have become embedded in supply contracts, with co-manufacturers offering bench-to-shelf formulation under one roof, thereby shortening innovation cycles. Packaging lines shift toward PCR plastics and compostable films, aligned with retailer sustainability scorecards. This evolution reinforces the strategic relevance of food-grade contractors within the broader United States contract manufacturing services market.
By Beverage: Functional Formats Drive Co-Packing Innovation
Bottled Water retained a 40.27% hold on 2024 beverage revenue, leveraging logistics simplicity and uniform demand curves. Functional RTD Beverages, projected at a 10.53% CAGR, draw on immunity, energy, and gut-health claims that create formulation complexity unsuited to legacy soda lines. Cold-fill aseptic tunnels, nitrogen dosing, and high-shear blending push capex thresholds upward, promoting outsourcing. Within the United States contract manufacturing services market, small-batch canning lines see near-full utilization as health-oriented startups race to retail.
Carbonated Drinks and Fruit-based Beverages maintain steady flow due to flavour rotation requirements and region-specific taste profiles. Sport Drinks contracting benefits from electrolyte-balance R&D, driving adoption of on-line conductivity meters for tight spec adherence. Beer co-manufacturing supports craft and seasonal releases, smoothing capacity for big brewers during shoulder periods. As multi-pack configurations diversify, contractors install combination packers and digital printers to accommodate SKUs without long changeovers. This flexibility remains a signature differentiator for beverage-focused providers inside the United States contract manufacturing services market.
Note: Segment shares of all individual segments available upon report purchase
By Personal Care: Clean-Beauty Momentum Accelerates Specialized Manufacturing
Skin Care commanded 28.62% of 2024 revenue, reflecting active-ingredient sophistication and sterility standards that align well with GMP-trained labour pools. Clean-Beauty formulations, tracking a 9.60% CAGR, mandate preservative-free processes and traceable botanicals, both of which add analytical overhead that favours specialist contractors. The United States contract manufacturing services market size dedicated to natural and organic cosmetics broadens as retailers set “free-from” lists demanding verified sourcing.
Hair Care outsourcing grows via ammonia-free colorants and scalp-health serums that require micro-emulsion know-how. Make-Up and Colour Cosmetics partners capitalize on limited-edition drops by leveraging short-run filling lines and modular cleanrooms. Packaging shifts toward refillable and recyclable formats, placing an additional premium on suppliers who can integrate sustainable componentry. Firms such as Cosmetic Essence Innovations deploy in-house fragrance labs and compatibility testing, allowing turnkey development from ideation to lot release. Overall, compliance with FDA cosmetic regulations and EU Annex II ingredient bans boosts the technical bar, reinforcing the need for specialist capacity across the United States contract manufacturing services market.
Geography Analysis
The South leads the United States contract manufacturing services market, leveraging lower land costs, advantageous tax policies, and port access that minimize inbound raw-material expenses. North Carolina’s Research Triangle exemplifies the cluster effect, hosting Eli Lilly’s planned API campus and Merck’s USD 1 billion vaccine plant, each anchoring local supply chains. Texas and Georgia add momentum through right-to-work statutes and workforce training grants that make site selection financially attractive. As biologics and food processing plants co-locate near agricultural basins and research universities, the region’s share of United States contract manufacturing services market size continues to expand.
The Northeast remains the epicentre for high-complexity pharmaceutical and biotechnology work, concentrating cGMP biologics suites within proximity of major sponsors. Massachusetts’ Route 128 corridor and New Jersey’s Pharma Belt provide access to venture funding and a seasoned regulatory workforce. Despite elevated operational costs, premium billing rates offset overhead, sustaining investment in single-use bioreactors and high-potency suites. PCI Pharma’s aseptic expansion and Kindeva’s integrated drug-device campus highlight ongoing capacity growth. The region’s mature ecosystem ensures that the United States contract manufacturing services market share for specialized life-science offerings remains substantial.
The Midwest occupies a balanced portfolio role, serving food, beverage, and automotive supply chains. Illinois, Ohio, and Wisconsin benefit from freight-rail hubs and abundant agricultural inputs, underpinning expansions such as Covestro’s polycarbonate compounding in Ohio. Skilled labour from legacy manufacturing towns supports process-intensive lines, while land availability accommodates large-footprint plants. The West, led by California and Washington, tilts toward electronics, aerospace, and premium beverage co-packing, leveraging innovation centers and venture capital. Although utility rates and regulatory hurdles elevate cost profiles, proximity to tech clients justifies premium pricing. Together, these regions contribute to a diversified geographic mosaic that underpins resilience in the United States contract manufacturing services market.
Competitive Landscape
Moderate consolidation defines the United States contract manufacturing services market; with scale advantages most pronounced in regulated pharmaceutical segments. Top CDMOs pursue vertical integration, acquiring complementary assets that fill technology gaps and secure end-to-end contract scopes. PCI Pharma’s USD 365 million Rockford injectable packaging project demonstrates the capital required to win biologic volume and reinforces barriers to entry. Simultaneously, smaller niche specialists thrive by offering bespoke capabilities such as probiotic beverage fermentation or refillable cosmetic packaging, creating a dual-track competitive field.
Automation adoption accelerates as providers deploy cobotics, real-time analytics, and digital twins to decrease downtime and enhance regulatory audit readiness. These investments compress batch-release timelines, allowing contractors to offer accelerated launch programs that differentiate on speed. The United States contract manufacturing services market also witnesses strategic alliances between material suppliers and packagers to co-develop sustainable solutions, locking in downstream demand for recycled resins and bio-based polymers.
Private-equity interest remains robust, evident in Lewis & Clark Capital’s purchase of ChemRite CoPac and New Harbor Capital’s stake in FoodPharma, reflecting faith in outsourced manufacturing’s recurring-revenue profile. Cross-border moves, such as Syngene’s first U.S. biologics buy, signal inbound competition that could spur further M&A as domestic players protect share. Overall, capability expansion and specialization continue to shape the strategic playbook within the United States contract manufacturing services market.
United States Contract Manufacturing Services Industry Leaders
-
Catalent Pharma Solutions Inc.
-
Lonza Group AG
-
Amerilab Technologies Inc.
-
Brooklyn Bottling Group
-
KIK Consumer Products Inc.
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- May 2025: Milk Specialties Global acquired a 96,000 square-foot protein plant in Minnesota to grow snack and meat-alternative co-manufacturing capacity.
- May 2025: Aceto bought Biotron Laboratories and Talus Mineral Company, adding amino-acid chelation technology and two Utah plants to its ingredient manufacturing footprint.
- April 2025: PCI Pharma Services closed the purchase of Ajinomoto Althea’s aseptic fill-finish network in San Diego, adding pre-filled syringe and ADC capabilities.
- April 2025: Kindeva Drug Delivery and Meridian Medical Technologies merged, creating a combined CDMO for parenteral, inhalation, and transdermal products.
United States Contract Manufacturing Services Market Report Scope
Contract manufacturing is the outsourcing of previously performed by the manufacturer's production activities to a third party.
United States Contract Manufacturing Services Market is Segmented by (Pharmaceutical, Food processing & manufacturing, Beverage, and Personal Care).
| Active Pharmaceutical Ingredient (API) Manufacturing | Small Molecule |
| Large Molecule | |
| High-Potency API | |
| Finished Dosage Formulation Development and Manufacturing | Solid Dose Formulation |
| Liquid Dose Formulation | |
| Injectable Dose Formulation | |
| Secondary Packaging |
| Food Manufacturing Services | Convenience Foods |
| Bakery Products | |
| Confectionery Products | |
| Dairy Products | |
| Research and Development | |
| Food Packaging Services |
| Beer |
| Carbonated Drinks and Fruit-based Beverages |
| Bottled Water |
| Sport Drinks |
| Skin Care |
| Hair Care |
| Make-Up and Color Cosmetics |
| Others |
| By Pharmaceutical Services | Active Pharmaceutical Ingredient (API) Manufacturing | Small Molecule |
| Large Molecule | ||
| High-Potency API | ||
| Finished Dosage Formulation Development and Manufacturing | Solid Dose Formulation | |
| Liquid Dose Formulation | ||
| Injectable Dose Formulation | ||
| Secondary Packaging | ||
| By Food Processing and Manufacturing | Food Manufacturing Services | Convenience Foods |
| Bakery Products | ||
| Confectionery Products | ||
| Dairy Products | ||
| Research and Development | ||
| Food Packaging Services | ||
| By Beverage | Beer | |
| Carbonated Drinks and Fruit-based Beverages | ||
| Bottled Water | ||
| Sport Drinks | ||
| By Personal Care | Skin Care | |
| Hair Care | ||
| Make-Up and Color Cosmetics | ||
| Others | ||
Key Questions Answered in the Report
How large is the United States contract manufacturing services market in 2025?
The market stands at USD 248.11 billion in 2025 and is on course for USD 356.72 billion by 2030.
What CAGR is forecast for U.S. contract manufacturing services through 2030?
A 7.53% compound annual growth rate is projected during the 2025-2030 period.
Which pharmaceutical subsegment is growing the fastest?
High-Potency API manufacturing is forecast to post a 10.01% CAGR through 2030, the steepest within pharma services.
Which food category leads outsourcing demand?
Convenience Foods holds 37.42% of 2024 revenue, reflecting strong reliance on contract production lines.
Where is geographic growth most pronounced?
The South leads, buoyed by favorable tax regimes, lower land costs, and major pharmaceutical buildouts.
What strategic trend shapes competitive dynamics?
Providers invest heavily in automation and specialty acquisitions to secure high-value contracts and meet stricter FDA requirements.
Page last updated on: